Information  X 
Enter a valid email address

BioPharma Credit PLC (BPCR)

  Print   

Thursday 10 March, 2022

BioPharma Credit PLC

NOTICE OF FULL YEAR RESULTS

RNS Number : 3866E
BioPharma Credit PLC
10 March 2022
 

10 March 2022

BIOPHARMA CREDIT PLC

(the "Company") 

NOTICE OF FULL YEAR RESULTS

BioPharma Credit PLC (LSE: BPCR), the specialist life sciences debt investor, will announce its audited Full Year Results for the period ending 31 December 2021 on Tuesday 22 March 2022.

A management presentation will be delivered at 9:30am GMT at the offices of Buchanan, 107 Cheapside, EC2V 6DN and through a webcast facility for those unable to attend in person. To register to attend or request details, RSVP to [email protected].

-Ends-

 Enquiries

  BioPharma Credit PLC

via Link Company Matters Limited

Company Secretary

+44 (0) 1392 477 500

 

Buchanan

+44 (0)20 7466 5000

David Rydell / Mark Court / Jamie Hooper / Henry Wilson

[email protected]

 

Notes to Editors:

BioPharma Credit PLC is London's only listed specialist investor in debt from the life sciences industry and joined the LSE on 27 March 2017. The Company seeks to provide long-term shareholder returns, principally in the form of sustainable income distributions from exposure to the life sciences industry. The Company seeks to achieve this objective primarily through investments in debt assets secured by royalties or other cash flows derived from the sales of approved life sciences products.

LEI: 213800AV55PYXAS7SY24

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NORMZGMFDGKGZZM

a d v e r t i s e m e n t